市场调查报告书
商品编码
1395025
一次性生物反应器市场- 副产品(搅拌槽、波混合、鼓泡塔)、细胞(哺乳动物、细菌、酵母)、分子(单株抗体、疫苗、重组蛋白)、用途、最终用途- 全球预测, 2023 年-2032Single-use Bioreactors Market - By Product (Stirred Tank, Wave-mixed, Bubble Column), Cell (Mammalian, Bacterial, Yeast), Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins), Usage, End-use- Global Forecast, 2023-2032 |
在医疗保健领域的显着进步和一次性生物加工技术固有的灵活性的推动下,全球一次性生物反应器市场从 2023 年到 2032 年的CAGR将达到 15.5%。在精准医学和治疗创新激增的推动下,对生物製药的需求不断增长,凸显了这些进步的重要性。一次性生物反应器由于其适应性强且具有成本效益的性质,成为满足医疗保健行业不断变化的需求的关键工具,从而为行业格局做出了重大贡献。
例如,2023 年,Getinge 推出了 AppliFlex ST GMP,这是一种创新的一次性生物反应器系统,旨在顺利连接细胞和基因治疗的研究和临床生产领域以及 mRNA 生产。此次发布透过无缝整合尖端医疗保健进步和一次性生物加工技术的内在灵活性来提高市场份额。
一次性生物反应器市场根据分子、细胞和区域进行划分。
到 2032 年,单株抗体 (mAb) 领域将获得大幅成长。这种突出地位源自于 mAb 的治疗应用不断增加,特别是在治疗癌症和自体免疫疾病方面。它们的高特异性、治疗功效以及对个人化医疗不断增长的需求使其在生物加工领域中占据突出地位。随着製药领域优先考虑精准和标靶治疗,单株抗体在一次性生物反应器中的作用变得至关重要,从而塑造了生物反应器的市场前景。
由于细菌细胞在各种生物加工活动中的广泛应用,包括疫苗、酵素和生物治疗药物的生产,到 2032 年,细菌细胞细分市场将获得可观的收入份额。利用细菌细胞的多功能性、可扩展性和成本效益使其脱颖而出。随着对生物製药的需求不断升级,基于细菌细胞的製程的盛行将使它们成为塑造健康市场成长轨迹的关键驱动力。
受多种因素的推动,包括生物製药需求的成长、研发投资的增加以及生物技术产业的蓬勃发展,亚太地区一次性生物反应器市场规模将从 2023 年到 2032 年以显着的CAGR扩大。有利的监管环境,加上该地区强大的製造能力,有助于其突出地位。随着全球製药格局的不断发展,亚太市场成为关键贡献者,推动创新并塑造一次性生物反应器的未来。
Global Single-use Bioreactors Market will register a 15.5% CAGR from 2023 to 2032, propelled by the remarkable advancements in healthcare and the inherent flexibility of single-use bioprocessing technologies. The increasing demand for biopharmaceuticals, driven by a surge in precision medicine and therapeutic innovations, underscores the significance of these advancements. Single-use bioreactors, owing to their adaptable and cost-effective nature, emerge as pivotal tools in meeting the evolving needs of the healthcare sector, thereby significantly contributing to the industry landscape.
For instance, in 2023, Getinge launched the AppliFlex ST GMP, an innovative single-use bioreactor system crafted to smoothly connect the realms of research and clinical production in cell and gene therapy, along with mRNA production. This launch bolsters the market share by seamlessly integrating cutting-edge healthcare advancements and the intrinsic flexibility of single-use bioprocessing technologies.
The single-use bioreactors market is segregated based on molecule, cell, and region.
The monoclonal antibodies (mAbs) segment will garner substantial gains through 2032. This prominence stems from the increasing therapeutic applications of mAbs, particularly in treating cancer and autoimmune diseases. Their high specificity, therapeutic efficacy, and rising demand for personalized medicine contribute to their prominence in bioprocessing. As the pharmaceutical landscape prioritizes precision and targeted therapies, the role of monoclonal antibodies within single-use bioreactors becomes pivotal, shaping the bioreactors market outlook.
The bacterial cell segment will capture a remarkable revenue share by 2032 due to the widespread application of bacterial cells in various bioprocessing activities, including the production of vaccines, enzymes, and biotherapeutics. The versatility, scalability, and cost-effectiveness of utilizing bacterial cells contribute to their prominence. As the demand for biopharmaceuticals continues to escalate, the prevalence of bacterial cell-based processes will position them as a pivotal driver in carving a healthy market growth trajectory.
APAC single-use bioreactors market size will expand at a notable CAGR from 2023 to 2032, fueled by a confluence of factors, including the growing demand for biopharmaceuticals, increasing investments in research and development, and a burgeoning biotechnology sector. Favorable regulatory environments, in line with the region's robust manufacturing capabilities, contribute to its prominence. As the global pharmaceutical landscape continues to evolve, the Asia-Pacific market stands as a key contributor, driving innovation and shaping the future of single-use bioreactors.